NASDAQ:TXMD

TherapeuticsMD Q1 2026 Earnings Results & Report

TherapeuticsMD logo
$1.71 -0.10 (-5.52%)
As of 11/20/2026 04:00 PM Eastern

TherapeuticsMD beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of $0.01 versus the -$6.1250 consensus estimate, while revenue of $720 thousand fell short of the $19.77 million estimate by $19.05 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

TherapeuticsMD EPS Results

Actual EPS
$0.01
Consensus EPS
-$6.1250
Beat/Miss
Beat by +$6.1350
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

TherapeuticsMD Revenue Results

Actual Revenue
$720 thousand
Expected Revenue
$19.77 million
Beat/Miss
Missed by -$19.05 million
YoY Revenue Growth
N/A

TherapeuticsMD Q1 2026 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) reported earnings of $0.01 per share for Q1 2026, beating the consensus estimate of -$6.1250. The report was announced on Tuesday, May 12, 2026.

TherapeuticsMD reported revenue of $720 thousand for Q1 2026, against a consensus estimate of $19.77 million.

TherapeuticsMD Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market.

The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.

In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.

View TherapeuticsMD Profile